Results 211 to 220 of about 19,575 (260)
Some of the next articles are maybe not open access.
BLyS and BLyS receptor expression in non-Hodgkin's lymphoma
Experimental Hematology, 2002B Lymphocyte Stimulator (BLyS) protein and its receptor are new members of the tumor necrosis factor family, with specific effects exclusively on B cells. We have studied the tumor cell expression of the BLyS-Receptor (BLyS-R) and the serum BLyS protein levels in patients with different types of non-Hodgkin's lymphomas (NHL).BLyS-R expression was ...
Javier, Briones +3 more
openaire +2 more sources
Seminars in Immunology, 2006
Naïve peripheral B cells survive in vivo because of active stimulation by the TNF superfamily ligand B lymphocyte stimulator (BLyS/BAFF). Although the survival promoting properties of BLyS are well known, the signal pathways and molecular effectors that characterize this stimulation are still being elucidated.
Woodland, Robert T. +2 more
openaire +3 more sources
Naïve peripheral B cells survive in vivo because of active stimulation by the TNF superfamily ligand B lymphocyte stimulator (BLyS/BAFF). Although the survival promoting properties of BLyS are well known, the signal pathways and molecular effectors that characterize this stimulation are still being elucidated.
Woodland, Robert T. +2 more
openaire +3 more sources
The TNF superfamily is on the TRAIL to BlyS
Drug Discovery Today, 2003Highlights of the 9th (Biennial) International Congress on TNF-Related Cytokines (30 October-2 November 2002; The Manchester Grand Hyatt, San Diego, CA, USA.
Paul M, Steed, René S, Hubert
openaire +2 more sources
A therapeutic role for BLyS antagonists
Lupus, 2004B lymphocytestimulator (BLyS) is a vital B cell survivalfactor. Overexpressionof BLyS in mice may lead to systemic lupus erythematosus (SLE)-like disease, and treatment of bona fide SLE mice with BLyS antagonists ameliorates disease progression and enhances survival. BLyS overexpression is common in human SLE, and results from a phase I clinical trial
openaire +2 more sources
Harmony and BLyS in Europe and the UK
Pharmaceutical Patent Analyst, 2012*Marks & Clerk LLP, 62–68 Hills Road, Cambridge, CB2 1LA, UK Tel.: +44 1223 345 520 Fax: +44 1223 365 560 E-mail: gwilliams@marks-clerk.com Photograph © Marks & Clerk LLP What level of disclosure is required to obtain a patent? When asserting a physiological or therapeutic function of a molecule, how concrete must these functions be?
openaire +2 more sources